|Articles|November 1, 1997

November 1997
Volume 3
Issue 11

Enhancement of Compliance Among Patients with Hypertension

Author(s)Krista Patton, MD, John Meyers, MD, Barbara Edelman Lewis, PhD

Download PDF: Enhancement of Compliance Among Patients with Hypertension

Articles in this issue

over 28 years ago

Article

Empiric Examination of Physician Behavior in a Changing Healthcare Market

over 28 years ago

Article

Healthcare Utilization Among Women with Eating Disordered Behavior

over 28 years ago

Article

Postpartum Depression

over 28 years ago

Article

Pulmonary Rehabilitation: An Overview with Evidence for Its Utility in Chronic Obstructive Pulmonary Disease

over 28 years ago

Article

Pharmaceutical Considerations of Common Herbal Medicine

over 28 years ago

Article

Cardiovascular Drug Prescribing Patterns: Where is the Evidence of Improvement?

over 28 years ago

Article

When Is a Cost-Effectiveness Claim Valid? How Much Should the FDA Care?

over 28 years ago

Article

Treatment Patterns for Heart Failure in a Primary Care Environment

over 28 years ago

Article

Referrals to General Internists and Internal Medicine Trainees in an Academic Medicine Practice

over 28 years ago

Article

Incorporating Quality of Life Data into Managed Care Formulary Decisions: A Case Study with Salmeterol

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Enhancement of Compliance Among Patients with Hypertension

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

Prior Cancer History Predicts Second Cancers in Polycythemia Vera, Essential Thrombocythemia

Managing the Tafasitamab Triplet: Safety Profile, Adverse Events, and Clinical Implications from inMIND